{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:53:49Z","timestamp":1785884029893,"version":"3.56.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000194","name":"Nova Scotia Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014823","name":"VGH & UBC Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ekir.2026.106630","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:57:00Z","timestamp":1780415820000},"page":"106630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment"],"prefix":"10.1016","volume":"11","author":[{"given":"Malik","family":"El-Feghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D.","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurette","family":"Geldenhuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Finkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswathy","family":"Sunil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Wiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Y.C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106630_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev-med-050219-034449","article-title":"Clinical perspectives on IgG4-related disease and its classification","volume":"73","author":"Katz","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ekir.2026.106630_bib2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/hematology.2024000584","article-title":"IgG4-related disease for the hematologist","volume":"2024","author":"Chen","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ekir.2026.106630_bib4","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2026.106630_bib5","series-title":"\u00dcber eine eigenartige symmetrische Erkrankung der Tr\u00e4nen und Mundspeicheldr\u00fcsen. Beitr\u00e4ge zur Chirurgie Festschrift, Gewidmet Theodor Billroth von Seinen Dankbaren Sch\u00fclern zur Feier des Vollendeten 50 Semesters Seines Akademischen Wirkens in Wien","first-page":"610","author":"Mikulicz","year":"1892"},{"key":"10.1016\/j.ekir.2026.106630_bib6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1056\/NEJM200103083441005","article-title":"High serum IgG4 concentrations in patients with sclerosing pancreatitis","volume":"344","author":"Hamano","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106630_bib7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/ard-2023-223950","article-title":"Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults","volume":"82","author":"Wallace","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib8","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/art.39686","article-title":"IgG4-related disease: retrospective analysis of one hundred sixty-six patients","volume":"68","author":"Sekiguchi","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.autrev.2016.12.008","article-title":"IgG4-related disease: evidence from six recent cohorts","volume":"16","author":"Mart\u00ednez-Valle","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2026.106630_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib11","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.3390\/ijms21145082","article-title":"The cellular and molecular bases of allergy, inflammation and tissue fibrosis in patients with IgG4-related disease","volume":"21","author":"Hsieh","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106630_bib12","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.ekir.2024.05.011","article-title":"Clinicopathologic features of IgG4-related kidney disease","volume":"9","author":"Buglioni","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106630_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.0000000000000193","article-title":"Clinical and prognostic factors in patients with IgG4-related kidney disease","volume":"18","author":"Chaba","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4421589","article-title":"Renal manifestations of IgG4-related disease: a concise review","volume":"2024","author":"Towheed","year":"2024","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5527\/wjn.v7.i1.29","article-title":"Immunoglobulin G4-related kidney diseases: an updated review","volume":"7","author":"Salvadori","year":"2018","journal-title":"World J Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.ajkd.2003.12.006","article-title":"Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis","volume":"43","author":"Uchiyama-Tanaka","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/ndt\/gfg477","article-title":"IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis","volume":"19","author":"Takeda S-i","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106630_bib19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/PAS.0b013e318059b87c","article-title":"Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease","volume":"31","author":"Cornell","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ekir.2026.106630_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1681\/ASN.2011010062","article-title":"Diagnosis of IgG4-related tubulointerstitial nephritis","volume":"22","author":"Raissian","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ki.2010.271","article-title":"Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis","volume":"78","author":"Saeki","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106630_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2012.07.031","article-title":"IgG4-related tubulointerstitial nephritis with plasma cell-rich renal arteritis","volume":"61","author":"Sharma","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14397595.2018.1554321","article-title":"IgG4-related kidney disease and retroperitoneal fibrosis: an update","volume":"29","author":"Kawano","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/mr\/roac065","article-title":"Recent advances in IgG4-related kidney disease","volume":"33","author":"Kawano","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.semdp.2023.12.001","article-title":"IgG4-related kidney disease: clinicopathologic features, differential diagnosis, and mimics","volume":"41","author":"Gilani","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ekir.2026.106630_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102694","article-title":"Overview of IgG4-related aortitis and periaortitis. A decade since their first description","volume":"19","author":"Nikiphorou","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2026.106630_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13075-020-02197-w","article-title":"IgG4-related aortitis\/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease","volume":"22","author":"Peng","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2026.106630_bib34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3400\/avd.oa.19-00085","article-title":"Clinical and pathological characteristics of IgG4-related periaortitis\/periarteritis and retroperitoneal fibrosis diagnosed based on experts\u2019 diagnosis","volume":"12","author":"Mizushima","year":"2019","journal-title":"Ann Vasc Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib35","article-title":"Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis","volume":"16","author":"Wang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2026.106630_bib36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.mayocp.2015.03.020","article-title":"Diagnostic approach to the complexity of IgG4-related disease","volume":"90","author":"Stone","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 3","key":"10.1016\/j.ekir.2026.106630_bib38","doi-asserted-by":"crossref","first-page":"iii123","DOI":"10.1093\/rheumatology\/kez667","article-title":"IgG4-related disease: a clinical perspective","volume":"59","author":"Maritati","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2026.106630_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib41","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ekir.2022.09.019","article-title":"Clinicopathologic findings in mass forming ANCA-associated vasculitis","volume":"7","author":"Gilani","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106630_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cll.2019.07.005","article-title":"Diagnostic pitfalls in immunology testing","volume":"39","author":"Maher","year":"2019","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.ekir.2026.106630_bib43","article-title":"Interference of antinuclear antibody (ANA) in indirect immunofluorescence assay (IIFA)-based perinuclear antineutrophil cytoplasmic antibody (pANCA) interpretation","volume":"2022","author":"Deka","year":"2022","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib44","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1093\/rheumatology\/keaf020","article-title":"Anti-C1q antibodies in IgG4-related disease are common and associated with renal involvement and cutaneous small-vessel vasculitis","volume":"64","author":"Mart\u00edn-Nares","year":"2025","journal-title":"Rheumatology (Oxf Engl)"},{"issue":"1","key":"10.1016\/j.ekir.2026.106630_bib100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/art.38193","article-title":"Brief Report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease","volume":"66","author":"Khosroshahi","year":"2014","journal-title":"Arthritis Rheumatol. Jan"},{"key":"10.1016\/j.ekir.2026.106630_bib45","series-title":"Related Disease","first-page":"169","article-title":"IgG4-related kidney disease","author":"Saeki","year":"2013"},{"key":"10.1016\/j.ekir.2026.106630_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","article-title":"Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.crad.2023.03.003","article-title":"Imaging manifestations of IgG4-related disease","volume":"78","author":"Naik","year":"2023","journal-title":"Clin Radiol"},{"key":"10.1016\/j.ekir.2026.106630_bib48","doi-asserted-by":"crossref","first-page":"W276","DOI":"10.2214\/AJR.11.8321","article-title":"Systemic IgG4-related sclerosing disease: spectrum of imaging findings and differential diagnosis","volume":"199","author":"Horger","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ekir.2026.106630_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2214\/AJR.07.3629","article-title":"Retroperitoneal fibrosis: a review of clinical features and imaging findings","volume":"191","author":"Cronin","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ekir.2026.106630_bib51","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210105","article-title":"18F-FDG PET\/CT manifestations of IgG4-related disease","volume":"94","author":"Tang","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ekir.2026.106630_bib52","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1148\/rg.357150066","article-title":"IgG4-related disease from head to toe","volume":"35","author":"Mart\u00ednez-de-Alegr\u00eda","year":"2015","journal-title":"RadioGraphics"},{"key":"10.1016\/j.ekir.2026.106630_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2020.104014","article-title":"Pathological characteristics and diagnosis of IgG4-related disease","volume":"49","author":"Zen","year":"2020","journal-title":"Presse Med"},{"key":"10.1016\/j.ekir.2026.106630_bib54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ekir.2026.106630_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2020.104017","article-title":"Renal involvement in IgG4-related disease","volume":"49","author":"Boffa","year":"2020","journal-title":"Presse Med"},{"key":"10.1016\/j.ekir.2026.106630_bib56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrneph.2015.95","article-title":"IgG4-related disease and the kidney","volume":"11","author":"Cortazar","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ki.2012.382","article-title":"Membranous glomerulonephritis is a manifestation of IgG4-related disease","volume":"83","author":"Alexander","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106630_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10157-011-0521-2","article-title":"Proposal for diagnostic criteria for IgG4-related kidney disease","volume":"15","author":"Kawano","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10157-020-01993-7","article-title":"Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version","volume":"25","author":"Saeki","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2026.106630_bib60","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1148\/radiol.2423060003","article-title":"Renal involvement in patients with autoimmune pancreatitis: CT and MR imaging findings","volume":"242","author":"Takahashi","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2026.106630_bib61","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1097\/RHU.0000000000001787","article-title":"IgG4-related disease: mimickers and diagnostic pitfalls","volume":"28","author":"Mart\u00edn-Nares","year":"2022","journal-title":"JCR J Clin Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib62","first-page":"121","article-title":"Retroperitoneal fibrosis with periaortitis: a case report of an unusual form of presentation of granulomatosis with polyangiitis","volume":"19","author":"Gonz\u00e1lez Revilla","year":"2016","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.ekir.2026.106630_bib63","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000044915","article-title":"Retroperitoneal fibrosis with perinuclear antineutrophil cytoplasmic antibodies and a longitudinally extended periaortic soft-tissue structure on CT","volume":"78","author":"Sakemi","year":"1998","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2026.106630_bib64","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3348\/kjr.2015.16.5.1056","article-title":"Immunoglobulin G4-related kidney disease: a comprehensive pictorial review of the imaging spectrum, mimickers, and clinicopathological characteristics","volume":"16","author":"Seo","year":"2015","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.ekir.2026.106630_bib65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11739-016-1599-z","article-title":"Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease","volume":"12","author":"Rossi","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ekir.2026.106630_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1376723","article-title":"Immunoglobulin G4 in primary Sj\u00f6gren\u2019s syndrome and IgG4-related disease-connections and dissimilarities","volume":"15","author":"Maslinska","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106630_bib67","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.34593","article-title":"Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations","volume":"64","author":"Stone","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2026.106630_bib68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0090-1229(77)90013-7","article-title":"Sj\u00f6gren\u2019s syndrome with immune-complex tubulointerstitial renal disease","volume":"8","author":"Winer","year":"1977","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.ekir.2026.106630_bib69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.31662\/jmaj.2021-0113","article-title":"Immunoglobulin G4-related disease: a new systemic disease emerging in Japan","volume":"5","author":"Kamisawa","year":"2022","journal-title":"JMA J"},{"key":"10.1016\/j.ekir.2026.106630_bib70","first-page":"275","article-title":"The treatment outcomes in IgG4-related disease","volume":"76","author":"Karim","year":"2018","journal-title":"Neth J Med"},{"key":"10.1016\/j.ekir.2026.106630_bib71","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","article-title":"Management of IgG4-related disease","volume":"1","author":"Zhang","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ekir.2026.106630_bib99","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14397595.2016.1259602","article-title":"A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease","volume":"27","author":"Masaki","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib76","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ard.2025.01.033","article-title":"Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study","volume":"84","author":"Chen","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib77","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1038\/s41598-017-06520-5","article-title":"Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids","volume":"7","author":"Yunyun","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2026.106630_bib78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","article-title":"Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial","volume":"58","author":"Yunyun","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2026.106630_bib81","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib88","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib85","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106630_bib94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ard.2025.05.199","article-title":"Efficacy and safety of rilzabrutinib, an oral bruton's tyrosine kinase inhibitor, in patients with IgG4-related disease: results from a 52-week, phase 2, open-label, proof-of-concept study","volume":"84","author":"Stone","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib72","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib73","series-title":"IgG4-related kidney disease: diagnostics, manifestations and more","author":"Michailidou","year":"2023"},{"key":"10.1016\/j.ekir.2026.106630_bib74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11926-020-00966-9","article-title":"Into clinical practice: diagnosis and therapy of retroperitoneal fibrosis","volume":"23","author":"Fenaroli","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ekir.2026.106630_bib75","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial","volume":"378","author":"Vaglio","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106630_bib79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine"},{"key":"10.1016\/j.ekir.2026.106630_bib80","article-title":"Therapeutic uses of rituximab and clinical features in immunoglobulin G4-related disease: a systematic review","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ekir.2026.106630_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.ekir.2026.106630_bib83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.006","article-title":"Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis","volume":"127","author":"Liu","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ekir.2026.106630_bib84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2020.12.006","article-title":"Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study","volume":"84","author":"Della-Torre","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"Suppl 5","key":"10.1016\/j.ekir.2026.106630_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2026.106630_bib87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/mr\/roac141","article-title":"Perspectives on current and emerging therapies for immunoglobulin G4\u2013related disease","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ekir.2026.106630_bib90","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2019-216368","article-title":"Dupilumab as a novel steroid-sparing treatment for IgG4-related disease","volume":"79","author":"Simpson","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003026","article-title":"IgG4-related disease administered dupilumab: case series and review of the literature","volume":"9","author":"Kanda","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ekir.2026.106630_bib92","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1093\/rheumatology\/keab950","article-title":"Therapeutic potential of the interleukin-4\/interleukin-13 inhibitor dupilumab for treating IgG4-related disease","volume":"61","author":"Nakajima","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106630_bib93","article-title":"AB0756 immune-mediated basis for a PHASE 2A clinical study comparing rilzabrutinib VS glucocorticoids in rituximab-refractory patients with IgG4-related disease","volume":"80","author":"Long","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2026.106630_bib95","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ekir.2026.106630_bib96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:29:10Z","timestamp":1785882550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926028627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2468024926028627"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106630","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106630"}}